PDL1 Amplifications Mark Subset of Solid Tumors, May Point to Checkpoint Blockade Response

Jun 15, 2018

|

NEW YORK (GenomeWeb) – A subset of solid tumors containing PDL1 amplifications appear more prone to respond to immune checkpoint blockade immunotherapy, even in the absence of high PD-L1 protein expression, microsatellite instability (MSI), or enhanced tumor mutational burden (TMB).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Featured White Papers

FFPE Controls for Use with Ion AmpliSeq and Oncomine ALK, RET, and ROS1 Fusion Assays

Modular DNA Assembly of PIK3CA Using Acoustic Liquid Transfer in Nanoliter Volumes

Effective Miniaturization of Illumina Nextera XT Library Prep for Multiplexed Whole Genome Sequencing and Microbiome Applications

High-Throughput Microliter-Sized Cell-Free Transcription-Translation Reactions for Synthetic Biology Applications Using the Echo 550 Liquid Handler

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

04

Featured Webinar

Software Tools for NGS-Based Diagnosis of CFTR-Related Diseases in Routine Practice

This webinar will discuss the use of new software tools to support the diagnosis of CTFR-related disorders using next-generation sequencing.

Oct

10

Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Main menu